[Skip to Content]

Upstate Active Clinical Trials

Study Title:

ACNS1833 - A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

What is the purpose of the study? (in Layman's terms, please describe the study)

Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Upstate Institutional Review Board (IRB) Number:

1762877

Study/Protocol ID:

ACNS1833

Study Phase:

III

Patient Age Group:

Adults and Children

Principal Investigator:

Melanie A Comito

Who is eligible?

Patients must be ≥ 2 years and ≤ 21 years at the time of enrollment.

What is involved if I participate?

  • How long is the study?
    approx 2 years
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    surgery, blood draws, lumbar puncture, imaging

Where will the study take place?

SUNY Upstate Medical University

Other Information:

N/A

Who can I contact for more information?

Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]

Return to Previous Page || Search Again

Top